A comprehensive guide to the top data in genitourinary oncology presented at ESMO 2026.

Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.

Topline results from the study are anticipated in the first half of 2027.

The 2026 LUGPA Annual Meeting will tackle policy, artificial intelligence, and practice growth, according to Benjamin H. Lowentritt, MD, FACS.

JNJ-6143 demonstrated promising PSA and tumor response rates with an encouraging safety profile in heavily pretreated mCRPC, including across genomic subgroups.

Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.

In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.

Updated CAPItello-281 data showed a clinically meaningful benefit in OS when capivasertib was added to abiraterone and ADT in PTEN-deficient mHSPC.